SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending following the release of pivotal Phase 3 trial data for its pancreatic cancer candidate, daraxonrasib, which significantly improved overall survival compared to standard chemotherapy. Investors and clinicians are actively discussing the transformative clinical outcomes, which have sparked heightened acquisition speculation and multiple analyst price target increases as the company advances its regulatory filings.

GSI Technology, Inc. engages in the design, development and marketing of memory products primarily for the networking, and telecommunications markets. Its product includes Static Random Access Memory, or SRAM, which incorporated in networking and telecommunications equipment, such as routers, switches, wide area network infrastructure equipment, wireless base stations and network access equipment. It also offers services to the ongoing needs of the military, industrial, test and measurement equipment, automotive and medical markets for SRAMs .The company was founded by Lee-Lean Shu and Robert Yau in March 1995 and is headquartered in Sunnyvale, CA.

GSI Technology Inc

GSI Technology is trending as investors react to a U.S. Army xTech SBIR contract win for its Gemini-II APU and anticipation regarding its potential role in edge AI and defense sectors. While some community members are bullish on its specialized compute-in-memory architecture, others remain highly skeptical, frequently warning of dilution risks and questioning the competitiveness of their product compared to established industry leaders.

BlackRock, Inc. engages in the provision of investment, advisory, and risk management solutions. Its products include single-asset and multi-asset portfolios. The company was founded by Laurence Douglas Fink and Robert Steven Kapito in 1988 and is headquartered in New York, NY.

Blackrock Inc.

BlackRock is currently trending as the market scrutinizes its private credit division following reports of restricted investor withdrawals and rising loan stress in the sector. Traders are also actively debating the stock's technical position, with many analysts focusing on recent Elliott Wave analysis that identifies a critical support zone as the asset manager faces broader concerns about liquidity and potential systemic risks.

Affirm Holdings, Inc. operates a platform for digital and mobile-first commerce. Its platform consists of three core elements: a point-of-sale payment solution for consumers, merchant commerce solutions, and a consumer-focused app. The company was founded by Max R. Levchin in 2012 and is headquartered in San Francisco, CA.

Affirm Holdings Inc - Ordinary Shares - Class A

Affirm Holdings Inc

Affirm is currently trending as a focal point for fintech investors, with strong sentiment driven by its resilient recurring loan revenue and the expansion of its partnership with Google's AI-driven platforms. The community is actively debating the stock's long-term valuation versus cyclical credit risks, with many traders closely monitoring its price action for signs of a major breakout.

VanEck ETF Trust - VanEck Gold Miners ETF

VanEck Gold Miners ETF

The VanEck Gold Miners ETF (GDX) remains a focal point for investors as central banks aggressively expand their gold reserves to hedge against geopolitical fragmentation and sustained inflationary pressures. The community is actively debating the sector's long-term outlook, weighing the potential for a monetary reset and fiscal stimulus against short-term volatility driven by rate hike speculation and shifting dollar dynamics.

Axsome Therapeutics, Inc. is a commercial-stage biopharmaceutical company, which engages in the development of novel therapies for the management of central nervous system disorders. Its portfolio consists of Products Overview and Pipeline Overview. The Products Overview includes Auvelity and Sunosi. The Pipeline Overview refers to AXS-05, AXS-07, AXS-12, and AXS-14. The company was founded by Herriot Tabuteau on January 12, 2012 and is headquartered in New York, NY.

Axsome Therapeutics Inc

Axsome Therapeutics is attracting significant attention as investors anticipate the upcoming FDA decision on the supplemental New Drug Application for Auvelity to treat agitation associated with Alzheimers disease. The community is heavily focused on the drugs clean label potential and the company's aggressive sales force expansion, viewing the pending approval as a transformative catalyst for the firm's commercial growth.

Terra is a decentralized financial payment network that rebuilds the traditional payment stack on the blockchain. Luna is the reserve currency of the Terra platform. It has three core functions: i) mine Terra transactions through staking, ii) ensure the price stability of Terra stablecoins and iii) provide incentives for the platform’s blockchain validators.

Terra Luna Classic

Terra Luna Classic is trending as community members rally behind network upgrades and aggressive token burn initiatives, fueling speculation about a potential supply squeeze. Discussions remain polarized, balancing high-conviction support for a long-term underdog recovery against cautionary warnings regarding the token's massive circulating supply and historical volatility.

SharonAI Holdings, Inc. operates as a holding company that develops and delivers GPU cloud computing and AI solutions. The company was founded on December 30, 2024 and is headquartered in New York, NY.

SharonAI Holdings Inc. - Ordinary Shares - Class A

SharonAI is currently experiencing intense attention and high volatility driven by a massive multi-year infrastructure contract and strategic positioning from prominent institutional investors like Leopold Aschenbrenner's Situational Awareness. The community is actively debating the stock's potential for a major short squeeze due to its tight float, with many focusing on its role as a niche 'NeoCloud' provider amid broader AI hardware demand.

TokenOS is the world’s most advanced AI-powered Web3 development platform, designed to turn natural language prompts into fully functional, production-ready blockchain applications. From simple tokens and memecoins to complex DeFi protocols, TokenOS automates the creation, deployment, and auditing of smart contracts and dApps with enterprise-grade reliability. By combining advanced language models with blockchain infrastructure, TokenOS removes the barriers of technical expertise, making Web3 development accessible to everyone. With instant deployment, built-in security best practices, and cross-chain support on the roadmap, TokenOS empowers entrepreneurs, developers, and creators to launch tokenized businesses and decentralized applications in seconds.

TokenOS AI

TokenOS AI is trending as investors rally behind the v4 launch and a revenue-sharing model that distributes GPU network earnings to node runners and stakers. The community is heavily focused on the high percentage of supply locked in long-term staking, which is driving discussions around supply scarcity and potential long-term utility.

Sea Ltd. is an internet and mobile platform company, which engages in the provision of online gaming services. It operates through the following segments: Digital Entertainment, E-Commerce, and Digital Financial Services. The Digital Entertainment segment offers and develops mobile and PC online games. The E-Commerce segment manages a third-party marketplace through the Shopee mobile app and websites that connect buyers and sellers. The Digital Financial Services segment includes a variety of payment services and loans to individuals and businesses through SeaMoney. Sea was founded by Xiao Dong Li, Gang Ye, and Jing Ye Chen on May 8, 2009 and is headquartered in Singapore.

Sea Ltd - ADR

Sea Ltd is seeing significant downward price pressure following earnings results that underwhelmed investors despite continued revenue growth, fueling an intense community debate over whether the stock is a deep value opportunity or a deteriorating asset. The conversation is currently split between traders looking for technical bounces or long-term accumulation and those concerned about the company's competitive positioning, margin compression, and the broader macro impact of recent regional instability.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly

Dividend King vs. Growth Giant: Johnson & Johnson Takes on Eli Lilly...

Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?

Key PointsJohnson & Johnson's CEO recently explained that his company isn't going to get caught up in the GLP-1 weight loss drug race...

Can Medicare Bridge Help Novo Nordisk Defend Its GLP-1 Leadership?

NVO benefits from Medicare's GLP-1 Bridge, but equal coverage for rival therapies shifts the obesity race toward clinical differentiation and long-term outcomes.

Lilly Up Around 7% in a Week: Should You Buy, Sell or Hold the Stock?

LLY's leadership in GLP-1 therapies, expanding pipeline and diversified growth strategy support its long-term outlook despite a premium valuation.

Innovent, Eli Lilly Partner to Commercialize Breast Cancer Drug in China

Innovent and Eli Lilly sign a China commercialization deal for Verzenios, expanding patient access while Lilly retains manufacturing.read more...

Amgen or Biogen: Which Biotech Stock Appears Better Poised?

AMGN stands out compared to Biogen given its broader product portfolio, pipeline depth and steadier growth outlook despite patent and competition risks.

Zacks Investment Ideas feature highlights: Eli Lilly and Altria

Eli Lilly and Altria stand out as defensive stock ideas as investors weigh a hawkish Fed, a pivotal jobs report and shifting market leadership.

Weight Loss ETFs Poised to Rally as Medicare Greenlights GLP-1 Coverage

Medicare's new GLP-1 coverage could expand access to weight-loss drugs, making ETFs a diversified way to tap growth across the obesity treatment market.

Roche Gets FDA Priority Review for Enspryng in Thyroid Eye Disease

Roche won FDA priority review for Enspryng in thyroid eye disease, with a decision date in October and phase III data backing the filing.

Pivotal Week Ahead: Warsh's Hawkish Turn, June Jobs Report on Deck

The abbreviated week in the market could set the tone for the back half of 2026.

Eli Lilly & Co. engages in the discovery, development, manufacture, and sale of pharmaceutical products. The firm's products include diabetes, oncology, immunology, neuroscience, and other products and therapies. The company was founded by Eli Lilly on May 10, 1876 and is headquartered in Indianapolis, IN.

Lilly(Eli) & Co

HIMS Stock Eyes Big Monthly Win: Novo Nordisk Calls Hims & Hers One Of Its Most ‘Voluminous’ Telehealth Partners 

Equity

Bearish Sentiment

Hold rates steady

Cut 25 bps

Hike 25 bps

Fed decision day is here - Kevin Warsh chairs his first FOMC meeting with markets pricing a hold at 3.50%-3.75% but watching for a hawkish shift. Vote on what you expect to be decided today, then drop your prediction for the first rate cut or hike in the comments.

What do you expect the Fed to decide at its FOMC meeting today? 
 
Drop a comment with when you expect the first cut/hike to be.

Current Price	$1,213.91
Prev Close	$1,191.74
Open	$1,193.01
Dividend Yield	0.56%
50-Day Moving Average	$1,054.92
Beta	0.69
Avg. Volume	3.41M
PE Ratio	43.70

52-Week High	$1,238.00
52-Week Low	$623.78
Market Capitalization	$1.14T
EPS (Annual)	$22.95
Price to Book	36.71
Revenue Per Employee	$1.3M

Feed

News

Sentiment

Earnings

Fundamentals

Info

LLYLilly(Eli) & Co

Latest LLY News